NuVision Biotherapies is delighted to announce the appointment of its new chairman, Dr Mark Treherne.

Mark has a PhD in Pharmacology from Cambridge University along with over 25 years of industrial R&D experience in the discovery and development of novel treatments for diseases with unmet medical need. Mark is also currently Chairman of Talisman Therapeutics and Chief Executive of Avilex Pharma.

Prior to this, Mark has carried out research work with Pfizer and in 1997 set up Cambridge Drug Discovery (CDD) as Chief Executive which was sold to BioFocus in 2001.

Mark was formerly Chairman of ERBI for 3 years, which represents the biotechnology companies in the East of England (now One Nucleus). He was also Chief Executive of the Life Sciences Organisation of UK Trade & Investment until 2016. Mark is an author of over 70 articles published in the scientific and trade press.

Mark has worked with many early-stage biotechnology companies such as CDD, Xention, Ampika, Population Genetics Technologies, Domain Therapeutics, Cyclofluidic and NeuroSolutions. Mark has an impressive track record of working successfully with both large organisations and small start-up companies. He is therefore a valuable additional to the NuVision team.

Andrew Hopkinson, CEO of NuVision “Mark is an asset to NuVision’s next chapter, bringing a profile of skills and expertise that will help NuVision transform from an early stage start up to a fully fledged and successful SME ”.

Mark Treherne “I am delighted to join NuVision and am very much looking forward to working with the team to help take the Company through to its next stage of development”.